Impax gets FDA OK for Generic Agrylin and AVANIR Pharmaceuticals to at present 3rd annual Biotechnology Conference.

0 Comments | M2 Presswire, April, 2005

M2 PRESSWIRE-19 April 2005-US Financial Network: Impax gets FDA OK for Generic Agrylin and AVANIR Pharmaceuticals to at present 3rd annual Biotechnology Conference(C)1994-2005 M2 COMMUNICATIONS LTD RDATE:19042005 City of Industry, CA - Biotechnology industry news provided by Financial News USA (OTC: FNWU).

Impax Laboratories Inc. (NASDAQ: IPXLE) said it has received Food and Drug Administration approval for its generic version of Shire Pharmaceutical Group's (NASDAQ: SHPGY) Agrylin capsules. They are used to reduce the elevated platelet count and the risk of thrombosis, and to ameliorate associated symptoms of thrombocythemia, including thrombo-hemorrhagic events. Impax said it expects to launch the 0.5 mg and 1 mg capsules immediately. AVANIR...

Read the rest of this article with a Free Trial at HighBeam Research.
Premium Content Partnership | HighBeam Research provides an in-depth online archive library of reference works. HighBeam Research

 

BNET TalkbackShare your ideas and expertise on this topic

Please add your comment:
  1. You are currently: a Guest |
  4.  

Basic HTML tags that work in comments are: bold (<b></b>), italic (<i></i>), underline (<u></u>), and hyperlink (<a href></a)